Attached files
| file | filename |
|---|---|
| EX-99.1 - Eloxx Pharmaceuticals, Inc. | v207065_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): January 3,
2011
Senesco
Technologies, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
001-31326
|
84-1368850
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
303
George Street, Suite 420, New Brunswick, New Jersey
|
08901
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(732) 296-8400
|
|
(Registrant's
telephone number,
including
area code)
|
|
Not applicable
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
|
Item
8.01 Other Events.
On January 3, 2011, Senesco
Technologies, Inc. (the “Company”) announced that the U.S. Food and Drug
Administration (the “FDA”) has granted orphan drug designation for the Company’s
lead drug candidate, SNS01-T, for treatment of multiple myeloma. As a result,
the Company is eligible to receive a number of benefits, including tax credits,
access to grant funding for clinical trials, accelerated FDA approval, allowance
for marketing exclusivity after drug approval for a period of as long as seven
years and potential exemption from the FDA’s prescription drug application
fee.
On
January 3, 2011, the Company issued a press release announcing the grant of
orphan drug designation for SNS01-T for treatment of multiple myeloma. A copy of
this press release is attached hereto as Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Press
Release of Senesco Technologies, Inc. dated January 3,
2011.
|
-2-
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
SENESCO
TECHNOLOGIES, INC.
|
|||
|
Dated:
January 3, 2011
|
By:
|
/s/ Leslie J. Browne, Ph.D. | |
| Name: | Leslie J. Browne, Ph.D. | ||
| Title: | President and Chief Executive Officer | ||